Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
In June 2023, Starbucks attracted controversy for allegedly not allowing workers at some locations in 22 states to put up Pride Month decorations. It came during an ongoing public furor over the direction of LGBTQ+ rights in the US, with other major corporations, like Target and AB-InBev, which manufactures Bud Light, also receiving heightened criticism and scrutiny. A strike at some stores was announced as a result.
== Death == Farthing died on 6 April 2014 of a heart attack while travelling in a taxi in Hong Kong. His funeral was held at Church of St Michael and All Angels, an Anglican church in Christchurch on 22 April 2014. He is buried on Banks Peninsula.
== Adverse effects == The most common effects when taking dapoxetine are nausea, dizziness, dry mouth, headache, diarrhea, and insomnia. Discontinuation rates due to adverse effects and costs are very high, as demonstrated in a study in Asia which showed that cumulative discontinuation rates within one year are as high as 87%. Unlike other SSRIs used to treat depression, which have been associated with high incidences of sexual dysfunction, dapoxetine is associated with low rates of sexual dysfunction. Taken as needed, dapoxetine has very mild adverse effects of decreased libido (<1%) and erectile dysfunction (<4%).
Sources: en.wikipedia.org
Scott Boatwright, Chief Executive Officer and Board member Adam Rymer, Chief Financial Officer Curt Garner, President, Chief Strategy and Technology Officer Ilene Eskenazi, Chief Legal and Human Resources Officer Jason Kidd, Chief Operating Officer Laurie Schalow, Chief Corporate Affairs Officer Kerry Bridges, Chief Food Safety Officer
=== Off-label drugs === α2-Adrenergic receptor agonists (e.g., clonidine, guanfacine) Anticonvulsants/mood stabilizers (e.g., valproic acid, lamotrigine) Antipsychotics (non-licensed) (e.g., haloperidol, olanzapine) Cannabinoids (e.g., cannabis, dronabinol, nabilone) Dietary supplements (e.g., N-acetylcysteine, omega-3 fatty acids, sulforaphane) Entactogens (serotonin releasing agents) (e.g., MDMA) Melatonin receptor agonists (e.g., melatonin) NMDA receptor antagonists (e.g., memantine, amantadine) Norepinephrine reuptake inhibitors (NRIs) (e.g., atomoxetine) Opioid receptor antagonists (e.g., naltrexone) Other antidepressants (e.g., mirtazapine) Oxytocin receptor agonists (e.g., oxytocin) Probiotics and prebiotics Psychostimulants (norepinephrine–dopamine releasing agents and/or reuptake inhibitors) (e.g., amphetamine, methylphenidate) Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, sertraline, citalopram) Serotonergic psychedelics (e.g., psilocybin, lysergic acid diethylamide (LSD)) Serotonin–norepinephrine reuptake inhibitors (SNRIs) (e.g., milnacipran) Serotonin releasing agents (e.g., fenfluramine—withdrawn and no longer recommended) Serotonin 5-HT1A receptor agonists (e.g., buspirone) Tricyclic antidepressants (TCAs) (e.g., clomipramine)
Arenobufagin is believed to play a role in the regulation of the transport of water and electrolytes across cell membranes under physiological conditions. Experimental results show that Arenobufagin inhibits the sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) . It is one of the most potent blockers that are known to science, along with ouabain. It has been suggested that uncharged and non-polar amino acids may participate in the binding of arenobufagin to the extracellular surface of the ATPase. If this is the case, the steroid nucleus of arenobufagin probably also contributes to the binding. Furthermore, the presence of a sugar group in ouabain and the absence of one in arenobufagin suggests that it may me more lipophilic that ouabain and as such form a more stable complex with the Na+-K+ pump. Besides its effects on the Na+-K+ pump, arenobufagin also has some other effects on cells, which were discovered in experiment with cancer cell lines. It causes apoptosis by tempering with mitochondria. In cells treated with it, a decreasing mitochondrial potential was detected (in a dose-dependent manner), as well as a high Bax/Bcl-2 ratio, which is associated with apoptosis, or programmed cell death. Bax translocation from cytosol to mitochondria was also found to be increased. In addition to these effects, arenobufagin also induces morphological changes in organelles, blebbing of plasma membrane, shrinkage of nuclear membrane and chromatin condensation. These observation also indicate the occurrence of apoptosis.
== Limitations == Because the Edman degradation proceeds from the N-terminus of the protein, it will not work if the N-terminus has been chemically modified (e.g. by acetylation or formation of pyroglutamic acid). Sequencing will stop if a non-α-amino acid is encountered (e.g. isoaspartic acid), since the favored five-membered ring intermediate is unable to be formed. Edman degradation is generally not useful to determine the positions of disulfide bridges. Protein sequencing of attomole level of Edman degraded sequences are obtainable but require accelerator mass spectrometery which requires large, complex, and expensive equipment as well as 30 hours of bench time to analyze a single run.
Sources: en.wikipedia.org
== Gene == The PPY gene encodes an unusually short protein precursor of 95 amino acids in length. This precursor is cleaved to produce the signal peptide, the pancreatic polypeptide, the pancreatic icosapeptide, and a 5- to 7- amino-acid oligopeptide.
drug cartels in moving money to the U.S. While regulators have flagged money laundering problems at HSBC for nearly a decade, the bank continued to avoid compliance. In December 2012, HSBC settled for a $1.93 billion fine.
=== Post-RDS-1 === In the subsequent years it became increasingly valuable to gather information on the Soviet nuclear weapons program, which resulted in the development of technologies that could gather airborne particles in a WB-29 weather reconnaissance plane. On September 3, 1949, these particles were used to determine that the detonation time of the first Soviet atomic test, "Joe 1". Further analysis revealed that this bomb was a replicate of the "Fat Man", which was the bomb dropped on Nagasaki in 1945. This investigative methodology combined radiochemistry and other techniques to gather intelligence on nuclear activities. During the 1961 Soviet nuclear tests, most of the Novaya Zemlya shots were likely monitored by RB-47 aircraft flown from RAF Brize Norton and elsewhere. In August, Khrushchev had announced the existence 100 megaton Soviet bomb, ultimately tested as the Tsar Bomba. A JKC-135A was rapidly outfitted to monitor the test, under Operation Speed Light Bravo. Photomutiplier detectors in UV, visibile, and near-IR were used, with multiplication factors above 100 million. Cine and stills cameras were used, with lens resolutions up to 70 mm. One side of the aircraft was scorched. It has been argued that if the Tsar Bomba had been configured to yield 100 megatons instead of the decided 50, that the aircraft would have been destroyed. The United Kingdom worked with the US to monitor Soviet tests. RAF debris collection missions flew from the summer of 1949 from Scotland, Northern Ireland, and Gibraltar, filling the North Atlantic.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.